Caris Life Sciences Reports 45.4% Revenue Growth to $263.7 Million in Q2 2026

Caris Life Sciences, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $263.7 million for the three months ended June 30, 2026, a 45.4% increase from $181.4 million in the same period last year. The company's molecular profiling services, which accounted for the majority of revenue, surged by 54.8% to $252.3 million, driven by a rise in clinical case volume from approximately 50,000 to 59,200. However, revenue from pharma research and development services decreased by 38.0% to $11.5 million, attributed to the timing of service deliveries under existing agreements. For the six months ended June 30, 2026, total revenue was $479.9 million, up 58.7% from $302.3 million in the prior year.

The company reported a net loss of $0.6 million for the second quarter of 2026, a significant improvement compared to a net loss of $71.8 million in the same quarter of 2025. For the first half of 2026, the net loss was $1.1 million, compared to $174.4 million in the previous year. This turnaround is attributed to increased revenue and improved operational efficiencies, as reflected in an Adjusted EBITDA of $55.7 million for the second quarter, compared to $16.7 million in the prior year.

Operationally, Caris Life Sciences has expanded its product offerings, launching several new solutions in the second quarter, including Caris Detect, a multi-cancer early detection blood test, and Caris ChromoSeq, a combined assay for evaluating myeloid malignancies. The company also introduced Caris MI Clarity, a digital prognostic solution for breast cancer. These product launches are expected to enhance the company's market position and drive future revenue growth.

As of June 30, 2026, Caris reported total assets of $1.23 billion, up from $1.13 billion at the end of 2025. The company’s cash, cash equivalents, and marketable securities totaled $794.9 million, providing a solid liquidity position to support ongoing operations and strategic initiatives. The company has also increased its employee headcount to support its growth, with a focus on expanding its sales and marketing capabilities.

Looking ahead, Caris Life Sciences anticipates continued growth driven by the expansion of its molecular profiling services and the successful adoption of its new product offerings. The company remains focused on enhancing its operational infrastructure to meet increasing demand and is committed to investing in research and development to drive innovation in precision medicine. However, the company acknowledges potential challenges, including the need for broad payer coverage and reimbursement for its solutions, which will be critical for sustaining revenue growth.